EXAGEN INC (XGN)
US30068X1037 - Common Stock
We assign a fundamental rating of 3 out of 10 to XGN. XGN was compared to 588 industry peers in the Biotechnology industry. XGN has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, XGN is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year XGN has reported negative net income.
In the past year XGN has reported a negative cash flow from operations.
In the past 5 years XGN always reported negative net income.
XGN had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
XGN has a Return On Assets (-41.60%) which is comparable to the rest of the industry.
XGN has a Return On Equity (-104.38%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -41.6% | ||
| ROE | -104.38% | ||
| ROIC | N/A |
ROA(3y)-39.45%
ROA(5y)-34.78%
ROE(3y)-82.51%
ROE(5y)-68.36%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 56.04%, XGN belongs to the top of the industry, outperforming 80.65% of the companies in the same industry.
In the last couple of years the Gross Margin of XGN has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for XGN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 56.04% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.54%
GM growth 5Y1.28%
2. Health
2.1 Basic Checks
XGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, XGN has more shares outstanding
The number of shares outstanding for XGN has been increased compared to 5 years ago.
Compared to 1 year ago, XGN has a worse debt to assets ratio.
2.2 Solvency
XGN has an Altman-Z score of -6.08. This is a bad value and indicates that XGN is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -6.08, XGN is not doing good in the industry: 65.75% of the companies in the same industry are doing better.
XGN has a Debt/Equity ratio of 0.86. This is a neutral value indicating XGN is somewhat dependend on debt financing.
XGN has a Debt to Equity ratio of 0.86. This is in the lower half of the industry: XGN underperforms 76.37% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.86 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.08 |
ROIC/WACCN/A
WACC7.31%
2.3 Liquidity
XGN has a Current Ratio of 4.02. This indicates that XGN is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 4.02, XGN perfoms like the industry average, outperforming 45.03% of the companies in the same industry.
XGN has a Quick Ratio of 4.02. This indicates that XGN is financially healthy and has no problem in meeting its short term obligations.
XGN has a Quick ratio (4.02) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.02 | ||
| Quick Ratio | 4.02 |
3. Growth
3.1 Past
XGN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 50.00%, which is quite impressive.
XGN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 15.32%.
The Revenue has been growing by 10.13% on average over the past years. This is quite good.
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q62.65%
Revenue 1Y (TTM)15.32%
Revenue growth 3Y7.77%
Revenue growth 5Y10.13%
Revenue growth Q2Q7.2%
3.2 Future
The Earnings Per Share is expected to grow by 9.97% on average over the next years. This is quite good.
The Revenue is expected to grow by 16.58% on average over the next years. This is quite good.
EPS Next Y-2.88%
EPS Next 2Y11.92%
EPS Next 3Y14.92%
EPS Next 5Y9.97%
Revenue Next Year7.66%
Revenue Next 2Y11.83%
Revenue Next 3Y13.88%
Revenue Next 5Y16.58%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for XGN. In the last year negative earnings were reported.
Also next year XGN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
XGN's earnings are expected to grow with 14.92% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.92%
EPS Next 3Y14.92%
5. Dividend
5.1 Amount
No dividends for XGN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EXAGEN INC
NASDAQ:XGN (4/26/2024, 7:25:06 PM)
1.4121
+0 (+0.15%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap24.34M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -41.6% | ||
| ROE | -104.38% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 56.04% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.92
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.86 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.02 | ||
| Quick Ratio | 4.02 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-2.88%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)15.32%
Revenue growth 3Y7.77%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y